NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI)

Toxicol Lett. 2016 Jan 5;240(1):105-13. doi: 10.1016/j.toxlet.2015.10.028. Epub 2015 Nov 3.

Abstract

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) cell signaling pathway is important in inflammation and cell survival. Inflammation and cell death in the kidney are features of cisplatin-induced AKI. While it is known that cisplatin induces NF-κB signaling in the kidney, the NF-κB responsive genes and the effect of direct NF-κB transcriptional inhibition in cisplatin-induced AKI is not known. Mice injected with cisplatin, 25mg/kg, developed AKI, acute tubular necrosis (ATN) and apoptosis on day 3. Mice were treated with JSH-23 (20 or 40 mg/kg) which directly affects NF-κB transcriptional activity. Kidney function, tubular injury (ATN, serum neutrophil gelatinase-associated lipocalin [NGAL], but not apoptosis) and myeloperoxidase (MPO) activity were significantly improved by JSH-23 (40 mg/kg). Sixty one NF-κB responsive genes were increased by cisplatin of which 21 genes were decreased by JSH-23. Genes that were decreased by JSH-23 that are known to play a role in cisplatin-induced AKI were IL-10, IFN-γ, chemokine [C-C motif] ligand 2 (CCL2) and caspase-1. Another gene, caspase recruitment domain family, member 11 (CARD11), not previously known to play a role in AKI, was increased more than 20-fold and completely inhibited by JSH-23. CXCL1 and TNF-α, known mediators of cisplatin-induced AKI, were decreased by JSH-23. RIPK1 and 3, receptor-interacting serine/threonine-protein kinases, that play an important role in necroptosis, were decreased by JSH-23. In mouse proximal tubule cells in culture, JSH-23 resulted in an increase in apoptosis suggesting that the mechanism of protection against AKI by JSH-23 is not due to a direct effect on proximal tubules. In conclusion, NF-κB transcriptional inhibition in cisplatin-induced AKI ameliorates kidney function and ATN without a significant effect on apoptosis and is associated with a decrease pro-inflammatory mediators and CARD11.

Keywords: Acute kidney injury; Apoptosis; Cisplatin; NF-κB; Necrosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acute-Phase Proteins
  • Animals
  • Apoptosis / drug effects
  • Blood Urea Nitrogen
  • CARD Signaling Adaptor Proteins / genetics
  • CARD Signaling Adaptor Proteins / metabolism
  • Caspase 1 / genetics
  • Caspase 1 / metabolism
  • Cells, Cultured
  • Chemokine CXCL1 / blood
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Creatinine / blood
  • Dose-Response Relationship, Drug
  • Interleukin-1 / blood
  • Interleukin-6 / blood
  • Kidney Tubular Necrosis, Acute / chemically induced
  • Kidney Tubular Necrosis, Acute / drug therapy*
  • Kidney Tubules, Proximal / cytology
  • Kidney Tubules, Proximal / drug effects
  • Kidney Tubules, Proximal / metabolism
  • Lipocalin-2
  • Lipocalins / blood
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics*
  • NF-kappa B / metabolism
  • Oncogene Proteins / blood
  • Peroxidase / metabolism
  • Phenylenediamines / pharmacology*
  • Receptor-Interacting Protein Serine-Threonine Kinases / genetics
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism
  • Signal Transduction
  • Transcriptional Activation*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine
  • Acute-Phase Proteins
  • CARD Signaling Adaptor Proteins
  • Card11 protein, mouse
  • Chemokine CXCL1
  • Cxcl1 protein, mouse
  • Interleukin-1
  • Interleukin-6
  • Lipocalin-2
  • Lipocalins
  • NF-kappa B
  • Oncogene Proteins
  • Phenylenediamines
  • Tumor Necrosis Factor-alpha
  • Lcn2 protein, mouse
  • Creatinine
  • Peroxidase
  • Receptor-Interacting Protein Serine-Threonine Kinases
  • Ripk1 protein, mouse
  • Ripk3 protein, mouse
  • Caspase 1
  • Cisplatin